Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action

被引:207
作者
Ganter, B [1 ]
Tugendreich, S [1 ]
Pearson, CI [1 ]
Ayanoglu, E [1 ]
Baumhueter, S [1 ]
Bostian, KA [1 ]
Brady, L [1 ]
Browne, LJ [1 ]
Calvin, JT [1 ]
Day, GJ [1 ]
Breckenridge, N [1 ]
Dunlea, S [1 ]
Eynon, BP [1 ]
Furness, LM [1 ]
Ferng, J [1 ]
Fielden, MR [1 ]
Fujimoto, SY [1 ]
Gong, L [1 ]
Hu, C [1 ]
Idury, R [1 ]
Judo, MSB [1 ]
Kolaja, KL [1 ]
Lee, MD [1 ]
McSorley, C [1 ]
Minor, JM [1 ]
Nair, RV [1 ]
Natsoulis, G [1 ]
Nguyen, P [1 ]
Nicholson, SM [1 ]
Pham, H [1 ]
Roter, AH [1 ]
Sun, DX [1 ]
Tan, SQ [1 ]
Thode, S [1 ]
Tolley, AM [1 ]
Vladimirova, A [1 ]
Yang, J [1 ]
Zhou, ZM [1 ]
Jarnagin, K [1 ]
机构
[1] Iconix Pharmaceut, Mountain View, CA 94043 USA
关键词
gene expression; microarray; contextual database; chemogenomics; drug discovery; toxicogenomics; lead optimization; carmustine; bile duct hyperplasia;
D O I
10.1016/j.jbiotec.2005.03.022
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Successful drug discovery requires accurate decision making in order to advance the best candidates from initial lead identification to final approval. Chemogenomics, the use of genomic tools in pharmacology and toxicology, offers a promising enhancement to traditional methods of target identification/validation, lead identification, efficacy evaluation, and toxicity assessment. To realize the value of chemogenomics information, a contextual database is needed to relate the physiological outcomes induced by diverse compounds to the gene expression patterns measured in the same animals. Massively parallel gene expression characterization coupled with traditional assessments of drug candidates provides additional, important mechanistic information, and therefore a means to increase the accuracy of critical decisions. A large-scale chemogenomics database developed from in vivo treated rats provides the context and supporting data to enhance and accelerate accurate interpretation of mechanisms of toxicity and pharmacology of chemicals and drugs. To date, approximately 600 different compounds, including more than 400 FDA approved drugs, 60 drugs approved in Europe and Japan, 25 withdrawn drugs, and 100 toxicants, have been profiled in up to 7 different tissues of rats (representing over 3200 different drug-dose-time-tissue combinations). Accomplishing this task required evaluating and improving a number of in vivo and microarray protocols, including over 80 rigorous quality control steps. The utility of pairing clinical pathology assessments with gene expression data is illustrated using three anti-neoplastic drugs: carmustine, methotrexate, and thioguanine, which had similar effects on the blood compartment, but diverse effects OD hepatotoxicity. We will demonstrate that gene expression events monitored in the liver can be used to predict pathological events occurring in that tissue as well as in hematopoietic tissues. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:219 / 244
页数:26
相关论文
共 19 条
  • [1] Senescent erythrocytes:: Factors affecting the aging of red blood cells
    Biondi, C
    Cotorruelo, C
    Ensinck, A
    Borrás, SG
    Racca, L
    Racca, A
    [J]. IMMUNOLOGICAL INVESTIGATIONS, 2002, 31 (01) : 41 - 50
  • [2] HUMAN DELTA-AMINOLEVULINATE SYNTHASE - ASSIGNMENT OF THE HOUSEKEEPING GENE TO 3P21 AND THE ERYTHROID-SPECIFIC GENE TO THE X-CHROMOSOME
    BISHOP, DF
    HENDERSON, AS
    ASTRIN, KH
    [J]. GENOMICS, 1990, 7 (02) : 207 - 214
  • [3] Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells
    Burczynski, ME
    McMillian, M
    Ciervo, J
    Li, L
    Parker, JB
    Dunn, RT
    Hicken, S
    Farr, S
    Johnson, MD
    [J]. TOXICOLOGICAL SCIENCES, 2000, 58 (02) : 399 - 415
  • [4] High-throughput variation detection and genotyping using microarrays
    Cutler, DJ
    Zwick, ME
    Carrasquillo, MM
    Yohn, CT
    Tobin, KP
    Kashuk, C
    Mathews, DJ
    Shah, NA
    Eichler, EE
    Warrington, JA
    Chakravarti, A
    [J]. GENOME RESEARCH, 2001, 11 (11) : 1913 - 1925
  • [5] DNA microarrays in drug discovery and development
    Debouck, C
    Goodfellow, PN
    [J]. NATURE GENETICS, 1999, 21 (Suppl 1) : 48 - 50
  • [6] Hamadeh HK, 2002, TOXICOL SCI, V67, P219, DOI 10.1093/toxsci/67.2.219
  • [7] Role of scaffolds in MAP kinase pathway specificity revealed by custom design of pathway-dedicated signaling proteins
    Harris, K
    Lamson, RE
    Nelson, B
    Hughes, TR
    Marton, MJ
    Roberts, CJ
    Boone, C
    Pryciak, PM
    [J]. CURRENT BIOLOGY, 2001, 11 (23) : 1815 - 1824
  • [8] Options available - from start to finish - for obtaining data from DNA microarrays
    Holloway, AJ
    van Laar, RK
    Tothill, RW
    Bowtell, DDL
    [J]. NATURE GENETICS, 2002, 32 (Suppl 4) : 481 - 489
  • [9] Classification of a large microarray data set: Algorithm comparison and analysis of drug signatures
    Natsoulis, G
    El Ghaoui, L
    Lanckriet, GRG
    Tolley, AM
    Leroy, F
    Dunlea, S
    Eynon, BP
    Pearson, CI
    Tugendreich, S
    Jarnagin, K
    [J]. GENOME RESEARCH, 2005, 15 (05) : 724 - 736
  • [10] Nuwaysir EF, 1999, MOL CARCINOGEN, V24, P153, DOI 10.1002/(SICI)1098-2744(199903)24:3<153::AID-MC1>3.0.CO